RHINOMED'S LOUD FULL YEAR RESULT

RHINOMED'S LOUD FULL YEAR RESULT
SNORING and sleep aid specialists Rhinomed (ASX: RNO) woke shareholders with a record full year result on the ASX.

The Melbourne company took in unaudited revenues of $1.01 million for the financial year, up 134 per cent on the previous year.

Strong June sales of Rhinomed's one-year-old over-the-counter snoring and sleep quality product, Mute, helped generate unaudited revenues of $298,000 for quarter four, a 57 per cent increase over the previous quarter.

Store count now totals over 2400 globally for the brand, with the recent addition of US-based Walgreens and Duane Reade more than doubling Mute's global footprint.

The company also sent its first shipment of stock to its Canadian distributor, McArthur Medical.

In Australia, Rhinomed products are carried by 600 retailers: Symbion, Sigma and Direct Pharmacies.

Due to such rapid expansion, costs have been high but 'expenditure is not anticipated to continue at these levels' as the company grows awareness, store presence and improves promotional opportunities. Mute marketing could be ramped up though, as Turbine marketing is curtailed. Turbine is Rhinomed's sports breathing technology.

Mute has only been available in the US for just over one month and the UK for six months, so the company forecasts strong sales performance in the September quarter.

Read more about Rhinomed taking the Big Apple in its US sleep market push.


Get our daily business news

Sign up to our free email news updates.

 
Whitefox Recruitment founder Luke Hemmings making strides as a careers leader
Partner Content
After relocating his Canberra-founded company Whitefox Recruitment to the Gold Coast la...
Whitefox Recruitment
Advertisement

Related Stories

ASIC secures its first court win for greenwashing against US giant Vanguard

ASIC secures its first court win for greenwashing against US giant Vanguard

The Australian corporate watchdog has caught out one of the world&r...

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Australian-founded medicinal cannabis company Althea Group (ASX: AG...

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Listed funds manager 360 Capital Group (ASX: TGP) has offloaded its...

Lendlease gains approval for $1.7b transformation of Queen Victoria Market precinct

Lendlease gains approval for $1.7b transformation of Queen Victoria Market precinct

Australian development giant Lendlease Group (ASX: LLC) has been gr...